ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Digital cognition plus plasma p-Tau217 and Aβ42/40 powerfully predict Alzheimer's progression.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Digital cognition plus plasma p-Tau217 and Aβ42/40 powerfully predict Alzheimer's progression.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionAlzheimer's disease is characterized by amyloid-β (Aβ) and tau accumulation. Identifying individuals with rapid proteinopathy progression is crucial for timely intervention and trial enrichment.
methodsWe analyzed longitudinal data from 456 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, including 375 with digital cognitive test scores. Amyloid and tau accumulation rates were estimated from positron emission tomography (PET) imaging using linear mixed-effects models. Participants were classified as fast or slow accumulators via Gaussian modeling. Predictors of accumulation and clinical conversion were assessed with logistic and Cox regression models, incorporating demographics, cognitive measures and plasma biomarkers.
resultsPlasma p-tau217 and Aβ42/Aβ40 predicted rapid accumulation and conversion, with p-tau217 the strongest marker (odds ratio [OR] up to 6.6). Baseline digital cognitive measures contributed significantly to the prediction, achieving comparable or superior predictive accuracy to traditional cognitive tests (area under the curve [AUC] up to 0.92; C-index 0.82). DISCUSSION: Plasma p-tau217 and Aβ42/Aβ40 emerged as robust predictors of the progression of disease pathology, supported by cognitive measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.